866-997-4948(US-Canada Toll Free)

Malignant Mesothelioma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Oncology

No. of Pages : 99 Pages

Malignant Mesothelioma - Pipeline Review, H1 2014

Summary

Global Markets Directs, Malignant Mesothelioma - Pipeline Review, H1 2014, provides an overview of the Malignant Mesotheliomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Malignant Mesothelioma Overview 9
Therapeutics Development 10
Pipeline Products for Malignant Mesothelioma - Overview 10
Pipeline Products for Malignant Mesothelioma - Comparative Analysis 11
Malignant Mesothelioma - Therapeutics under Development by Companies 12
Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes 14
Malignant Mesothelioma - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Malignant Mesothelioma - Products under Development by Companies 18
Malignant Mesothelioma - Products under Investigation by Universities/Institutes 19
Malignant Mesothelioma - Companies Involved in Therapeutics Development 20
Kyowa Hakko Kirin Co., Ltd. 20
Eli Lilly and Company 21
MedImmune, LLC 22
Aduro BioTech, Inc. 23
Bayer AG 24
Aeolus Pharmaceuticals, Inc. 25
Bionomics Limited 26
Biotecnol, Inc. 27
Advantagene, Inc. 28
Y's Therapeutics Co., Ltd. 29
SentoClone International AB 30
Verastem, Inc. 31
Formula Pharmaceuticals, Inc. 32
Malignant Mesothelioma - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 38
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
tremelimumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
BNC-105 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Oshadi D - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
FPI-01 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Oshadi D + Oshadi R - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
YS-110 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BIW-8962 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Drug For Mesothelioma - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AEOL-10150 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CRS-207 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BAY-949343 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
LY-3023414 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
VS-4718 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
BERTA - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Ad5-SGE-REIC/Dkk3 Gene Therapy - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Bivalent Bispecific Tribody - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Monovalent Trispecific Tribody - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
YP-223 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
YYP-218 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
YP-3 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SentoClone - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Malignant Mesothelioma - Recent Pipeline Updates 77
Malignant Mesothelioma - Dormant Projects 88
Malignant Mesothelioma - Discontinued Products 89
Malignant Mesothelioma - Product Development Milestones 90
Featured News & Press Releases 90
Jan 22, 2014: European Commission Grants Orphan Drug Status to Eisai's Amatuximab for the Treatment of Malignant Mesothelioma 90
Sep 19, 2013: Verastem Reports on Ongoing Trials at Cancer Advance at Harvard Medical School 90
Jul 24, 2013: Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma 91
Jun 13, 2013: Verastem Receives Orphan Medicinal Product Designation From European Commission For VS-6063 In Mesothelioma 92
Apr 17, 2013: Polaris Scientific Colleagues Present Data Demonstrating Metabolic Changes Induced By ADI-PEG 20 Are Associated With Anticancer Activity In Bladder Cancer And Mesothelioma Models At AACR Annual Meeting 2013 92
Feb 14, 2013: Verastem Files For Orphan Disease Status For VS-6063 In Mesothelioma 93
Jan 09, 2013: Verastem Enters Biomarker Agreement With LabCorp For Cancer Stem Cell Agent Companion Diagnostic 94
Nov 09, 2012: Verastem Reports Data On Focal Adhesion Kinase Program At 2012 EORTC Symposium On Molecular Targets And Cancer Therapeutics 95
Nov 08, 2012: GSK's Mesothelioma Drug Slows Disease Progression In Patients With Inactive NF2 Gene, Study Finds 96
Nov 05, 2012: Virttu Biologics Launches Replicate Open Innovation Forum To Provide R&D Network For New Oncology Combination Therapies 97
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 99
Disclaimer 99

List of Table

List of Tables
Number of Products under Development for Malignant Mesothelioma, H1 2014 10
Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Comparative Analysis by Unknown Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Malignant Mesothelioma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 20
Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H1 2014 21
Malignant Mesothelioma - Pipeline by MedImmune, LLC, H1 2014 22
Malignant Mesothelioma - Pipeline by Aduro BioTech, Inc., H1 2014 23
Malignant Mesothelioma - Pipeline by Bayer AG, H1 2014 24
Malignant Mesothelioma - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2014 25
Malignant Mesothelioma - Pipeline by Bionomics Limited, H1 2014 26
Malignant Mesothelioma - Pipeline by Biotecnol, Inc., H1 2014 27
Malignant Mesothelioma - Pipeline by Advantagene, Inc., H1 2014 28
Malignant Mesothelioma - Pipeline by Y's Therapeutics Co., Ltd., H1 2014 29
Malignant Mesothelioma - Pipeline by SentoClone International AB, H1 2014 30
Malignant Mesothelioma - Pipeline by Verastem, Inc., H1 2014 31
Malignant Mesothelioma - Pipeline by Formula Pharmaceuticals, Inc., H1 2014 32
Assessment by Monotherapy Products, H1 2014 33
Assessment by Combination Products, H1 2014 34
Number of Products by Stage and Target, H1 2014 37
Number of Products by Stage and Mechanism of Action, H1 2014 40
Number of Products by Stage and Route of Administration, H1 2014 42
Number of Products by Stage and Molecule Type, H1 2014 44
Malignant Mesothelioma Therapeutics - Recent Pipeline Updates, H1 2014 77
Malignant Mesothelioma - Dormant Projects, H1 2014 88
Malignant Mesothelioma - Discontinued Products, H1 2014 89

List of Chart

List of Figures
Number of Products under Development for Malignant Mesothelioma, H1 2014 10
Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 33
Number of Products by Top 10 Target, H1 2014 35
Number of Products by Stage and Top 10 Target, H1 2014 36
Number of Products by Top 10 Mechanism of Action, H1 2014 38
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 39
Number of Products by Top 10 Route of Administration, H1 2014 41
Number of Products by Stage and Top 10 Route of Administration, H1 2014 42
Number of Products by Top 10 Molecule Type, H1 2014 43
Number of Products by Stage and Top 10 Molecule Type, H1 2014 44

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *